A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational
- Sponsors Novartis Pharmaceuticals
- 08 Mar 2018 Planned End Date changed from 27 May 2019 to 18 Apr 2019.
- 08 Mar 2018 Planned primary completion date changed from 6 Nov 2018 to 18 Sep 2018.
- 08 Mar 2018 Status changed from recruiting to active, no longer recruiting.